(NEW YORK)–International Endeavors Corporation (OTCMKTS: IDVV) stock rallied on the appointment of cannabis veteran Steve Kubby as new CEO of IDVV.
IDVV stock rallied on news that they would be moving into the biomedical aspect of cannabis pharmaceutical research, and had appointed cannabis veteran Steve Kubby as new CEO of the company.
The Company announced a deal with Kubby Cryogenics Inc.in which Steve Kubby will immediately become CEO of International Endeavor Corporation (“IDVV”).
Steve Kubby was formally Chairman and CEO of Cannabis Sativa Inc., traded under the symbol (OTCMKTS:CBDS).
Mr. Kubby played a key role in the passage of California Proposition 215, a ballot initiative passed in 1996 to legalize medical marijuana. He is a well-known cancer patient of 36 years, who benefits his recovery through the use of non-psychoactive Cryogenics, a raw cannabis extract. and has authored 2 books on drug policy reform. Mr. Kubby’s distinguished political career includes runs for Governor of California in 1998, and the 2008 Presidential primary race under the libertarian ticket.
Kubby Cryogenics, along with IDVV, will look to patent medical grade cannabis strains that are genetically profiled to treating specific diseases.
The company will be acquiring licensing rights to patent new delivery systems in the future. Further, the company will continue with product development in their own proprietary Cryogenics line, which captures the highest medical value of any product known on the market today.
To accomplish these goals, Kubby Cryogenics has assembled a team of top Scientists and Geneticists to research and develop the strains for these Cryogenic Extract products.
Steve Kubby, the new CEO of International Endeavors commented, “We are very excited to partner with IEC, and anticipate bringing a new class of medicine to the market through our pure line of medical grade cannabis products featuring our patent pending Cryogenic process. We will create a dispensary system for legal medical cannabis states standardizing the patient centered, consultation approach while presenting an enticing line of Adult Use products featuring a patent pending menu of powerful strains and pure, all natural, solvent-less concentrate products.”
Cryogenics Medical Uses
Cancer, Fibromyalgia, Arthritis, High Blood Pressure, Epilepsy, Brain Injury, Stroke, Inflammation, and PTSD.
About International Endeavors Corporation
International Endeavors Corporation is a company focused on biomedical uses of non-psychoactive cannabis based products for the treatment of a wide variety of illnesses. Through a unique patent pending Cryogenic process, the Company can process different unique medical grade cannabis strains that are genetically profiled to treating specific diseases. www.internationalendeavorscorp.com